Curis (CRIS) – Press Releases
-
Curis Provides Fourth Quarter 2023 Business Update
-
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
-
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
-
Curis Announces Three Presentations at ASH
-
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
-
Curis Provides Third Quarter 2023 Business Update
-
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer
-
Curis to Present at Upcoming Healthcare Conferences in September
-
Curis Provides Second Quarter 2023 Business Update
-
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023
-
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
-
Curis Announces $15.1 Million Registered Direct Offering
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis Provides First Quarter 2023 Business Update
-
Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis to Present at Upcoming Healthcare Conferences in April
-
Curis Provides Fourth Quarter 2022 Business Update
-
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call
-
Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023
-
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS
-
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia
-
Curis Provides Third Quarter 2022 Business Update
-
Curis Announces Three Presentations at SITC 2022
-
Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis Announces Date for the 1st Symposium on IRAK4 in Cancer
-
Curis Announces Date for the 2nd Annual VISTA Symposium
-
Curis to Present at Upcoming Healthcare Conferences in September
-
FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study
-
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
-
Curis Reports Second Quarter 2022 Financial Results and Business Update
-
Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
-
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
-
Curis to Present at 2022 Jefferies Global Healthcare Conference
-
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
-
Curis Reports First Quarter 2022 Financial Results and Business Update
-
Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022
-
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis to Present at 21st Annual Needham Virtual Healthcare Conference
-
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
-
Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers
Back to CRIS Stock Lookup